Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07855757 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant Ascites

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To evaluate the efficacy and safety of retlirafusp alfa in combination with SOX chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma with malignant ascites, and to explore potential biomarkers associated with treatment response.
Trial Details
NCT Number NCT07855757
Lead Sponsor Zhejiang Cancer Hospital
Conditions
(from sponsor)		 Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer, Ascites, Malignant
Related terms Ascites, Stomach Neoplasms
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov